American Heart Journal
Volume 147, Issue 2 , Page 238 , February 2004

Which β-blocker for heart failure?

  • Manesh R Patel, MD

      Affiliations

    • Division of Cardiology and the Duke Clinical research Institute, Duke University Medical Center, Durham,NC, USA
    • Corresponding Author InformationReprint request: Manesh Patel, MD, Duke Clinical Research Institute, PO Box 17969, Durham,NC 27715, USA.
    • ,
  • Wendy Gattis, PharmD

      Affiliations

    • Division of Cardiology and the Duke Clinical research Institute, Duke University Medical Center, Durham,NC, USA

References 

  1. Packer M, Coats AJ, Fowler MB, et al.  Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  2. MERIT-HF Investigators . Effect of metoprolol CR/XL in chronic heart failure (metoprolol CR/XL randomised intervention trial in congestive heart failure). Lancet. 1999;353:2001–2007
  3. CIBIS-II Investigators . The cardiac insufficiency bisoprolol study II (CIBIS-II) (a randomised trial). Lancet. 1999;353:9–13
  4. Waagstein F, Bristow MR, Swedberg K, et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy (metoprolol in dilated cardiomyopathy (MDC) trial study group). Lancet. 1991;342:1441–1446
  5. BEST Investigators . A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667

PII: S0002-8703(03)00885-8

doi: 10.1016/j.ahj.2003.12.021

American Heart Journal
Volume 147, Issue 2 , Page 238 , February 2004

Article Tools